• 대한의생명과학회지
• /
• 제3권2호
• /
• pp.107-114
• /
• 1997

전립선특이 항원 (PSA: Prostate Specific Antigen)은 전립선 세포에서 분비되는 단백질로서 장기 특이성이 높아 전립선암의 조기진단 및 치료의 예후를 판단하기 위해 임상에서 널리 사용되고 있는 혈청 종양표지검사의 대상항원이다. 그러나 혈청 PSA치는 전립선암 뿐 아니라 양성 전립선질환인 전립선비대증 (BPH), 전립선 경색, 전립선 염증 등에서도 상승될 수 있다. 혈청 내의 PSA는 여러 가지 분자형태로 이루어져 있으며 대표적으로 ${alpha}_1$-antichymotrypsin과 결합된 결합형 PSA(PSA-ACT)와 유리형 PSA (free PSA)로 나눌 수 있다. 전립선 암 환자의 혈청에는 결합형 PSA가 95% 이상으로 매우 높고 유리형 PSA의 분포는 매우 작은 반면 전립성비대증에서는 유리형 PSA의 농도가 높아지므로, 결합형 PSA와 동시에 유리형 PSA를 측정하면 종양표지검사로서의 특이성과 예민도를 높일 수 있다는 보고가 있어, 최근 혈청내의 유리형 PSA의 측정의 중요성이 임상적으로 대두되고 있다. 이에 본 연구에서는 sandwich 원리로 유리형 PSA 효소면역 측정법 (EIA) kit를 개발하고 그 유용성을 검토한 결과, 고, 저 농도에서의 일내, 일간 변이 계수 (CV)는 4% 이하였으며 상품화된 free PSA kit와 비교하였을 때 두 방법간의 상관계수는 0.9965으로 매우 양호하였다. 또한 농도가 높은 세 환자의 검체를 희석하여 직선성 검사를 하였을 때 상관계수가 모두 0.995이상으로 나타났다. 또한 microplate 법에서 문제될 수 있는 hook effect는 유리형 PSA농도가 40 ng/mL까지 나타나지 않았으며, 98.9%~104.1%의 회수율을 나타내었다. 따라서 본 연구에서 개발한 면역측정법 kit는 혈청 중의 유리형 PSA를 정확하고 간편하게 분석할 수 있으므로 임상 실험실에서 전립선암이나 전립선질환의 진단 및 치료효과의 판정에 유용하게 사용될 수 있을 것으로 기대된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권6호
• /
• pp.2941-2946
• /
• 2016

Background: The limitations of total serum PSA values remain problematic, especially after an initial negative prostate biopsy. In this prospective study of Chilean men with a continued suspicion of prostate cancer due to a persistently elevated total serum PSA, abnormal digital rectal examination and initial negative prostate biopsy were compared with the use of the on-line Chun nomagram, detection of primary malignant circulating prostate cells (CPCs) and free percent PSA to predict a positive second prostate biopsy. We hypothesized that men negative for circulating prostate cells have a small risk of clinically significant prostate cancer and thus may be conservatively observed. Men positive for circulating prostate cells should undergo biopsy to confirm prostate cancer. Materials and Methods: Consecutive men with a continued suspicion of prostate cancer underwent 12 core TRUS prostate biopsy; age, total serum PSA and percentage free PSA and Chun nomagram scores were registered. Immediately before biopsy an 8ml blood simple was taken to detect primary mCPCs. Mononuclear cells were obtained by differential gel centrifugation and identified using double immunostaining with anti-PSA and anti-P504S. Biopsies were classifed as cancer/no-cancer, mCPC detecton test as negative/positive and the total number of cells/8ml registered. Areas under the curve (AUC) for percentage free PSA, Chun score and CPCs were calculated and compared. Diagnostic yields were calculated with reference to the number of possible biopsies that could be avoided and the number of clinically significant cancers that would be missed. Results: A total of 164 men underwent a second biopsy; 41 (25%) had cancer; the AUCs were 0.65 for free PSA, 0.76 for the Chun score and 0.87 for CPC detection, the last having a significantly superior prediction value (p=0.01). Using cut off values of free PSA <10%, Chun score >50% and ${\geq}1$ CPC detected, CPC detection had a higher diagnostic yield. Some 4/41 cancers complied with the criteria for active surveillance, free PSA and the Chun score missed a higher number of significant cancers when compared with CPC detection. Conclusions: Primary CPC detection outperformed the use of free PSA and the Chun nomagram in predicting clinically significant prostate cancer at repeat prostate biopsy.

• 보험의학회지
• /
• 제29권1호
• /
• pp.16-21
• /
• 2010

The measurement of prostate specific antigen (PSA) in screening for prostate cancer is recently performed as a routine check-up in clinical medicine and insurance medicine. Several factors may affect serum PSA levels. As prostate size increases with increasing age, the PSA concentration also rises. Increasing body mass index (BMI) is associated with a lower mean PSA concentration. Inhibitors of 5-alpha-reductase such as finasteride and dutasteride produce a 50 percent or greater decrease in serum PSA during the first three months of therapy, which persists as long as the drug is continued. Men who are regularly taking non-steroidal antiinflammatory drugs (NSAIDs) or acetaminophen have lower PSA levels. Emerging concepts regarding PSA testing that may help refine the interpretation of an elevated concentration include: PSA density, PSA velocity, and Free versus complexed or bound PSA. With many insurance companies, PSA level has become part of a standard battery of blood tests, along with HIV, cholesterol, liver enzymes, and other predictors of premature death. But, there is no clear proof of benefit, so we have to monitor the value of PSA test as a prostate cancer screening test in insurance medicine.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권13호
• /
• pp.5261-5264
• /
• 2015

Purpose: To examine the effectiveness of serum free-to-total prostate specific antigen ratio (%fPSA) for the detection of prostate cancer (PCa) in men with different serum total PSA (tPSA) categories. Materials and Methods: From January 2010 to December 2013, a total of 225 patients with lower urinary tract symptoms (LUTS) underwent tPSA and %fPSA measurements. Histological examination with calculation of Gleason score and whole body bone scans were performed in identified cases of PCa. Results: PCa was diagnosed in 44 (19.6%) patients and the remaining 181 patients had benign prostate disease. PCa was detected in 5 (23.8%), 13 (8.7%) and 26 (47.3%) cases with tPSA level ranges ${\leq}4ng/ml$, 4 to 10 ng/ml and >10 ng/ml, respectively. The average Gleason score was $7.2{\pm}0.2$. Some 6 (13.6%) out of 44 PCa patients had bone metastases. The sensitivity was 80% and specificity was 81.3% at the cut-off %fPSA of 15% in PCa patients with a tPSA level below 4 ng/mL. A lower %fPSA was associated with PCa patients with Gleason score ${\geq}7$ than those with Gleason score ${\leq}6$ ($11.7{\pm}0.98$ vs. $16.5{\pm}2.25%$, P=0.029). No obvious relation of %fPSA to the incidence of bone metastasis was apparent in this study. Conclusions: The clinical application of %fPSA could help to discriminate PCa from benign prostate disease in men with a tPSA concentration below 4 ng/mL.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권16호
• /
• pp.7085-7088
• /
• 2015

Background: The high incidence of prostate cancer as the most common malignancy in males in many countries raises the question of developing reliable detection tests. The prostate specific antigen (PSA) test is the most widely used for screening for prostate cancer; however, its low specificity elevates the number of unnecessarily biopsies. Serum human kallikrein-2 (hK2) is considered as a promising marker, and especially its ratio to fPSA, for predicting the presence of malignancy to select the best choice referring to biopsy or surveillance. In this study, we investigated the role of hK2 and its combinations with other markers to discriminate prostate cancer from benign diseases in Syrian patients. Materials and Methods: In this prospective oriented cross-sectional cohort study, serum samples were collected from patients referred to many Hospitals in Damascus, Syria, between May 2011 and March 2012, and diagnosed with biopsy proven benign prostate hyperplasia (BPH) or prostate cancer (PCa). Serum was analyzed for hK2, PSA and fPSA, and the ratios of fPSA/PSA and hK2/fPSA were calculated. Results: We found that mean hK2/fPSA ratios were significantly higher (P=0.01) in prostate cancer patients than in the BPH or control groups. Also the ratio hk2/fPSA gave the largest area under the curve (AUC:0.96) which was significantly larger than for fPSA/PSA (AUC:0.41) indicative of higher specificity. Conclusions: Our results demonstrate that the ratio of hK2/fPSA might be superior to the use of fPSA/PSA alone. The hK2 could be shown to enhance the early detection of prostate cancer; especially the ratio hK2/fPSA improves specificity and hence may reduce the number of negative biopsies.

• Natural Product Sciences
• /
• 제10권6호
• /
• pp.277-283
• /
• 2004

Psammaplin A (PSA), a naturally occurring biophenolic compound has been demonstrated to deliver significant cytotoxicity to many cancer cell lines. In this article, we investigated the effect of PSA on cell cycle progression of lung cancer cells (A549). It was found that PSA could slightly perturb the cell cycle progression of A549 cells and lead to the cell cycle arrest at G2/M phase, indicating PSA might disturb the mitosis process of A549 cells. In addition, inspired by the two phenolic groups in the structure of PSA, the antioxidant activity of it has been evaluated. Although PSA was weak in scavenging the stable free radical 1,1-diphenyl-2-picrylhyrazyl (DPPH), it showed stronger ABTS radical scavenging activity than ascorbic acid in TEAC assay. Furthermore, it was found that PSA could effectively prevent DNA strand scission induced by oxidative stress. These results suggest that PSA have both cell cycle regulation and antioxidant activities. Herein, we suggest that PSA would be a very interesting and promising candidate to be developed as a multi-function drug.

• Elastomers and Composites
• /
• 제44권4호
• /
• pp.429-435
• /
• 2009

전분을 보호 콜로이드이자 공중합체로 사용하면서 아크릴 단량체인 뷰틸 아크릴레이트, 2-에틸 헥실 아크릴레이트, 아크릴 산을 사용하여 무유화 중합에 의해 점착제를 합성하였다. 전분의 함량이 증가할수록 점착제의 겔 함량은 증가하였고, 결과로서 전분 함량의 증가는 점착력과 유지력의 증가를 가져왔으며, 초기점착력은 감소하는 결과를 보였다. 접촉각 측정에서 점착제의 젖음성은 전분의 하이드록시 그룹에 의한 극성의 증가로 전분 함량이 증가함 따라 상승하였다. 생분해성을 간접적으로 측정하는 에멀젼의 시간에 따른 pH 측정에서 전분의 분해에 의한 유기산의 생성에 의해 전분 함량의 증가에 비례하여 pH가 감소하였다.

• 대한임상검사과학회지
• /
• 제45권1호
• /
• pp.5-8
• /
• 2013

In the specimen of free PSA in the low concentration, the result in % bias from our institution and comparable evaluation institution was -33.7% which is exceeded % bias ${\pm}20%$ ; however, it was the domestically allowable limit recommended by the laboratory accreditation commission for specimen at the low concentration. In this paper, the cause was accredited by instability of free PSA substance within the specimen, and the specimen stability test was performed according to CLSI documents GP29-A2. After the low and high concentration specimen were made, and rapidly cooled down in a deep freezer with $-30^{\circ}C$, serum of two concentrations was measured for 10 consecutive days with 3 times a day by Architect i2000 and observed a change in the mean value. As the results of two groups, there were changes in the established target value, and a change level was evaluated by calculating it with % bias. The low concentration specimen had no significant reduction until the 4 day lapse in cold storage. However, % bias were reduced by -17.5% from the 5 day lapse, by 21.5% after the 7 day lapse, and by -26.9% after the 9 day lapse. The frozen specimen had only intra-day variation for 10 days. In the high concentration specimen, bias began to show as -12.2% from the 3 day lapse in cold storage. There was reduction by -28.9% from the 5 day lapse, by -39% after the 7 day lapse, and by -42.9% after the 9 day lapse. In the frozen specimen, there was only intra-day variation like the low concentration specimen in cold storage.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권7호
• /
• pp.2601-2611
• /
• 2015

Prostate cancer, with a lifetime prevalence of one in six men, is the second cause of malignancy-related death and the most prevalent cancer in men in many countries. Nowadays, prostate cancer diagnosis is often based on the use of biomarkers, especially prostate-specific antigen (PSA) which can result in enhanced detection at earlier stage and decreasing in the number of metastatic patients. However, because of the low specificity of PSA, unnecessary biopsies and mistaken diagnoses frequently occur. Prostate cancer has various features so prognosis following diagnosis is greatly variable. There is a requirement for new prognostic biomarkers, particularly to differentiate between inactive and aggressive forms of disease, to improve clinical management of prostate cancer. Research continues into finding additional markers that may allow this goal to be attained. We here selected a group of candidate biomarkers including PSA, PSA velocity, percentage free PSA, $TGF{\beta}1$, AMACR, chromogranin A, IL-6, IGFBPs, PSCA, biomarkers related to cell cycle regulation, apoptosis, PTEN, androgen receptor, cellular adhesion and angiogenesis, and also prognostic biomarkers with Genomic tests for discussion. This provides an outline of biomarkers that are presently of prognostic interest in prostate cancer investigation.

• 한국대기환경학회지
• /
• 제9권1호
• /
• pp.101-106
• /
• 1993

In order to separate the Freon-12 and air mixture$(CF_2Cl_2/Air=0.1/99.9 vol.%)$ by pressure swing adsorption (PSA), the breakthrough curve was experimentally observed in a fixed bed adsorption column. A single adsorber was packed with various adsorbents such as, the activated carbon(S-AC, W-AC) and the molecular sieve(MS-5A, MS-13X). The order of appearance of breakthrough curve is MS-5A > MS-13X > W-AC > S-AC. The activated carbon was found to be more effective adsorbent for separating Freon-12 from the mixture than the molecular sieve was. From the experimental data obtained by the separation of Freon-12 gas out of the air stream in the steady-state PSA process cycle, whose size is the same one of column used for the breakthrough curve observation, it has been confirmed that Freon-rich gas could be obtained from the purge step of PSA and Freon-free air could be obtained from the adsorption step of PSA cycle.